[1]周　红,周江洪.卵巢癌组织中 DR-NM23的表达及对细胞增殖和转移的影响[J].现代检验医学杂志,2022,37(01):114-118.[doi:10.3969/j.issn.1671-7414.2022.01.024]
　ZHOU Hong,ZHOU Jiang-hong.Expression of DR-NM23 in Ovarian Cancer Tissue and Its Effect on Cell Proliferation and Metastasisy[J].Journal of Modern Laboratory Medicine,2022,37(01):114-118.[doi:10.3969/j.issn.1671-7414.2022.01.024]
点击复制

卵巢癌组织中 DR-NM23的表达及对细胞增殖和转移的影响()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年01期
页码:
114-118
栏目:
论　著
出版日期:
2022-01-15

文章信息/Info

Title:
Expression of DR-NM23 in Ovarian Cancer Tissue and Its Effect on Cell Proliferation and Metastasisy
文章编号:
1671-7414（2022）01-119-06
作者:
周　红; 周江洪
（中南大学湘雅医学院附属株洲医院妇科，湖南株洲 412000）
Author(s):
ZHOU Hong;  ZHOU Jiang-hong
（Department of Gynaecology, Zhuzhou Hospital Affiliated to Xiangya MedicalCollege of Central South University, Hunan Zhuzhou 412000, China）
关键词:
卵巢癌; DR-NM23; 增殖; 迁移; 侵袭子宫内膜癌; 长链非编码 RNA小核仁 RNA宿主基因 1; 增殖; 转移; 细胞周期
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.01.024
文献标志码:
A
摘要:
目的　探究 DR-NM23在卵巢癌组织中的表达及对细胞增殖和转移的影响。方法　收集卵巢癌肿瘤组织和癌旁组织各 68例，通过免疫组化染色检测 DR-NM23表达水平，分析绝经、肿瘤大小、分化程度、局部浸润、淋巴转移和远端转移与 DR-NM23表达水平的相关性。在 SKOV3细胞系中过表达、沉默 DR-NM23，分别得到 DR-NM23组和 SiDR-NM23组，与对照组（ NC组）相比，评估各组增殖、迁移和侵袭能力，以评估 DR-NM23在卵巢癌组织中的作用机制。结果　卵巢癌组织中 DR-NM23平均染色强度为 2.68±0.75，低于癌旁组织 7.05±2.05，差异具有统计学意义（ P<0.05）。卵巢癌组织中 DR-NM23表达水平与是否绝经、肿瘤大小以及局部浸润无相关性，差异均无统计学意义（ χ2=0.418, 0.864,
Abstract:
Objective　To explore the expression of DR-NM23 in ovarian cancer and its effect on cell proliferation andmetastasis. Methods　68 cases of ovarian cancer tissues and adjacent tissues were collected clinically, and the DR-NM23expression level was detected by immunohistochemistry, and the correlation of DR-NM23 expression level with menopause,tumor size, differentiation, local invasion, lymph node metastasis and distal metastasis was analyzed. Overexpression andsilencing of DR-NM23 in SKOV3 cell line were used to obtain DR-NM23 group and Si-NM23 group, respectively. Comparedwith the control group (NC group), the proliferation, migration and invasion ability of each group were evaluated for themechanism of DR-NM23 in ovarian cancer tissue. Results　The average staining intensity of DR-NM23 in ovarian cancer tissuewas (2.68±0.75), which was lower than that in adjacent tissues (7.05±2.05) with stastically significant difference (P<0.05).Whether there was no correlation in menopause, tumor size and local invasion with the expression level of DR-NM23 in ovariancancer tissue, the differences not were statistically significant（χ2=0.418, 0.864, 2.915, all P>0.05）. The expression level ofDR-NM23 was lower in tissues with poor differentiation, lymph node metastasis and distant metastasis, the differences werestatistically significant (χ2=6.678, 6.845, 8.215, all P<0.05). The CCK-8 absorbance (1.16±0.18), migration distance percentage(88.58%±5.48%) and invasive cells (207.26±13.52) of siDR-NM23 group was higher than that of NC group(0.68±0.11,62.34%±2.15%, 125.54±8.15), while DR-NM23 group(0.47±0.07, 45.12%±3.76%, 59.57±5.02) was lower than that of NCgroup, the differences were stastically significant (all P<0.05). Conclusion　DR-NM23 was lowly expressed in ovarian cancertissue, might has the effect of inhibiting the proliferation, migration and invasion of tumor cells.

参考文献/References:

[1] JIM H L, LIN Huiyi, TYRER J P, et al. Commongenetic variation in circadian rhythm genes and risk ofepithelial ovarian cancer(EOC)[J]. Journal of Geneticsand Genome Research, 2016, 2(2): 17-24.
[2] MOTOHARA T, FUJIMOTO K, TAYAMA S, et al.CD44 variant 6 as a predictive biomarker for distantmetastasis in patients with epithelial ovarian cancer[J].Obstetrics and Gynecology, 2016, 127(6): 1003-1011.
[3] FANG Jie, GUO Xueke, ZHENG Bo, et al. Correlationbetween NM23 protein overexpression and prognosticvalue and clinicopathologic features of ovarian cancer:a meta-analysis [J]. Archives of Gynecology andObstetrics, 2018, 297(2): 449-458.
[4] CHEN C W ,WANG H L, HUANG C W, et al. Twoseparate functions of NME3 critical for cell survivalunderlie a neurodegenerative disorder[J]. Proceedingsof the National Academy of Sciences of the UnitedStates of America, 2019, 116(2): 566-574.
[5] 袁建良, 蒋晓波, 曹方, 等．DR-NM23 在浸润性乳腺癌中的表达及与临床病理参数的关系[J]. 现代肿瘤医学, 2018, 26(23):3760-3763.YUAN Jianliang, JIANG Xiaobo, CAO Fang, et al.Expression of DR-NM23 protein in invasive breastcancer and its relationship with clinicopathologyparameters [J]. Journal of Modern Oncology, 2018, 26(23): 3760-3763.
[6] RICCIARDELLI C, LOKMAN N A, PYRAGIUS CE, et al. Keratin 5 overexpression is associated withserous ovarian cancer recurrence and chemotherapyresistance[J]. Oncotarget, 2017, 8(11): 17819-17832.
[7] SU Li, LIU Mingmei. Correlation analysis on theexpression levels of microRNA-23a and microRNA-23b and the incidence and prognosis of ovariancancer[J]. Oncology Letters, 2018, 16(1): 262-266.
[8] HOFF S, EPTING D, FALK N, et al. The nucleoside-diphosphate kinase NME3 associates with nephronophthisisproteins and is required for ciliary functionduring renal development[J]. The Journal of BiologicalChemistry, 2018, 293(39): 15243-15255.
[9] FARKAS Z, PETRIC M, LIU Xianghua, et al. Thenucleoside diphosphate kinase NDK-1/NME1 promotesphagocytosis in concert with DYN-1/Dynamin [J].FASEB Journal, 2019, 33(10): 11606-11614.
[10] MOHD FAHEM M, RASOOL R U, AHMAD S M,et al. Par-4 mediated Smad4 induction in PDAC cellsrestores canonical TGF-β/ Smad4 axis driving thecells towards lethal EMT[J]. European Journal of CellBiology, 2020, 99(4): 151076.
[11] 马俊, 蒋晓波, 张曦, 等. 尿PCA3 在前列腺癌中的临床价值[J]. 癌症进展, 2019, 17(1):41-44, 69.MA Jun, JIANG Xiaobo, ZHANG Xi, et al. The clinicalvalue of urine prostate cancer antigen 3 in prostatecancer [J]. Oncology Progress, 2019, 17 (1): 41-44, 69.
[12] QU Lijuan, LIANG Li, SU Juanjuan, et al. Inhibitoryeffect of upregulated DR-NM23 expression on invasionand metastasis in colorectal cancer [J]. EuropeanJournal of Cancer Prevention, 2013, 22(6): 512-522.
[13] FLENTIE K, GONZALEZ C, KOCHER B, et al.Nucleoside diphosphate kinase-3 (NME3) enhancesTLR5-Induced NFκB activation[J]. Molecular CancerResearch, 2018, 16(6): 986-999.

相似文献/References:

[1]顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(04):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
　GU Yi-feng,ZHU Zi-li,ZHANG Jin-ye,et al.Selecting the Best Cut-off Point of Serum HE-4 in Ovarian Cancer by ROC Curve[J].Journal of Modern Laboratory Medicine,2015,30(01):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
[2]郑福利,张颖,王建.血清S100A6检测对卵巢上皮性癌的诊断价值[J].现代检验医学杂志,2015,30(05):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
　ZHENG Fu-li,ZHANG Ying,WANG Jian.Study on Diagnostic Value of Detecting Serum S100A6 in the Epithelial Ovarian Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(01):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
[3]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
　ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(01):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[4]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
　XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[5]张 悦a,段海霞,暴 蕾a,等.microRNA-125b在葛根素诱导人卵巢癌细胞SKOV3凋亡中的作用研究[J].现代检验医学杂志,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
　ZHANG Yuea,DUAN Hai-xia,BAO Leia,et al.Role of MicroRNA-125b in Human Ovarian Cancer Cell SKOV3 Induced Apoptosis by Puerarin[J].Journal of Modern Laboratory Medicine,2017,32(01):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
[6]徐金良a,杜丹丹,翟志敏,等.卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义[J].现代检验医学杂志,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　XU Jin-lianga,DU Dan-dan,ZHAI Zhi-min,et al.Changes and Clinical Significance of Four Parameters of NLR,LMR, RDW and PLR in Patients with Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2018,33(01):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]马同敏,赵志强.血清CA125,STIP1和IGF-Ⅰ联合检测对卵巢癌的早期诊断价值研究[J].现代检验医学杂志,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
　MA Tong-min,ZHAO Zhi-qiang.Clinical Value of Combined Detection of Serum CA125,STIP1 and IGF-I Levels in Early Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
[8]张善弟,荆成宝,禹 梅.血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值[J].现代检验医学杂志,2018,33(06):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
　ZHANG Shan-di,JING Cheng-bao,YU Mei.Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
[9]刘 青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(02):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
　LIU Qing,DENG Hui-min,ZHOU Lin-tao,et al.Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(01):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
[10]侯 娟,蒋树立,滕长财.基于TCGA 数据库卵巢癌患者的miR-301b 表达量与生存状况生物信息学分析[J].现代检验医学杂志,2020,35(04):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
　HOU Juan,JIANG Shu-li,TENG Chang-cai.Bioinformatics Analysis of Mir-301b Expression and Survival Status of Patients with Ovarian Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(01):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]

备注/Memo

备注/Memo:
作者简介：周红（1986-），女，本科，主治医生，研究方向：妇科宫颈癌、卵巢癌治疗，E-mail:zhonghong538@163.com。
更新日期/Last Update: 1900-01-01